Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic analyses prioritized genetic aberrations and revealed hallmarks of iCCA pathogenesis. Aflatoxin signature was associated wit...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell Vol. 40; no. 1; p. 70
Main Authors: Dong, Liangqing, Lu, Dayun, Chen, Ran, Lin, Youpei, Zhu, Hongwen, Zhang, Zhou, Cai, Shangli, Cui, Peng, Song, Guohe, Rao, Dongning, Yi, Xinpei, Wu, Yingcheng, Song, Nixue, Liu, Fen, Zou, Yunhao, Zhang, Shu, Zhang, Xiaoming, Wang, Xiaoying, Qiu, Shuangjian, Zhou, Jian, Wang, Shisheng, Zhang, Xu, Shi, Yongyong, Figeys, Daniel, Ding, Li, Wang, Pei, Zhang, Bing, Rodriguez, Henry, Gao, Qiang, Gao, Daming, Zhou, Hu, Fan, Jia
Format: Journal Article
Language:English
Published: United States 10.01.2022
Subjects:
ISSN:1878-3686, 1878-3686
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic analyses prioritized genetic aberrations and revealed hallmarks of iCCA pathogenesis. Aflatoxin signature was associated with tumor initiation, proliferation, and immune suppression. Mutation-associated signaling profiles revealed that TP53 and KRAS co-mutations may contribute to iCCA metastasis via the integrin-FAK-SRC pathway. FGFR2 fusions activated the Rho GTPase pathway and could be a potential source of neoantigens. Proteomic profiling identified four patient subgroups (S1-S4) with subgroup-specific biomarkers. These proteomic subgroups had distinct features in prognosis, genetic alterations, microenvironment dysregulation, tumor microbiota composition, and potential therapeutics. SLC16A3 and HKDC1 were further identified as potential prognostic biomarkers associated with metabolic reprogramming of iCCA cells. This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in iCCA.
AbstractList We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic analyses prioritized genetic aberrations and revealed hallmarks of iCCA pathogenesis. Aflatoxin signature was associated with tumor initiation, proliferation, and immune suppression. Mutation-associated signaling profiles revealed that TP53 and KRAS co-mutations may contribute to iCCA metastasis via the integrin-FAK-SRC pathway. FGFR2 fusions activated the Rho GTPase pathway and could be a potential source of neoantigens. Proteomic profiling identified four patient subgroups (S1-S4) with subgroup-specific biomarkers. These proteomic subgroups had distinct features in prognosis, genetic alterations, microenvironment dysregulation, tumor microbiota composition, and potential therapeutics. SLC16A3 and HKDC1 were further identified as potential prognostic biomarkers associated with metabolic reprogramming of iCCA cells. This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in iCCA.
We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic analyses prioritized genetic aberrations and revealed hallmarks of iCCA pathogenesis. Aflatoxin signature was associated with tumor initiation, proliferation, and immune suppression. Mutation-associated signaling profiles revealed that TP53 and KRAS co-mutations may contribute to iCCA metastasis via the integrin-FAK-SRC pathway. FGFR2 fusions activated the Rho GTPase pathway and could be a potential source of neoantigens. Proteomic profiling identified four patient subgroups (S1-S4) with subgroup-specific biomarkers. These proteomic subgroups had distinct features in prognosis, genetic alterations, microenvironment dysregulation, tumor microbiota composition, and potential therapeutics. SLC16A3 and HKDC1 were further identified as potential prognostic biomarkers associated with metabolic reprogramming of iCCA cells. This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in iCCA.We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic analyses prioritized genetic aberrations and revealed hallmarks of iCCA pathogenesis. Aflatoxin signature was associated with tumor initiation, proliferation, and immune suppression. Mutation-associated signaling profiles revealed that TP53 and KRAS co-mutations may contribute to iCCA metastasis via the integrin-FAK-SRC pathway. FGFR2 fusions activated the Rho GTPase pathway and could be a potential source of neoantigens. Proteomic profiling identified four patient subgroups (S1-S4) with subgroup-specific biomarkers. These proteomic subgroups had distinct features in prognosis, genetic alterations, microenvironment dysregulation, tumor microbiota composition, and potential therapeutics. SLC16A3 and HKDC1 were further identified as potential prognostic biomarkers associated with metabolic reprogramming of iCCA cells. This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in iCCA.
Author Zhang, Xiaoming
Zhou, Jian
Lin, Youpei
Rodriguez, Henry
Lu, Dayun
Shi, Yongyong
Figeys, Daniel
Cai, Shangli
Rao, Dongning
Gao, Qiang
Zou, Yunhao
Ding, Li
Song, Guohe
Yi, Xinpei
Dong, Liangqing
Zhang, Zhou
Wang, Xiaoying
Fan, Jia
Zhang, Bing
Cui, Peng
Zhang, Xu
Gao, Daming
Liu, Fen
Wang, Shisheng
Song, Nixue
Qiu, Shuangjian
Wu, Yingcheng
Chen, Ran
Zhou, Hu
Zhu, Hongwen
Zhang, Shu
Wang, Pei
Author_xml – sequence: 1
  givenname: Liangqing
  surname: Dong
  fullname: Dong, Liangqing
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 2
  givenname: Dayun
  surname: Lu
  fullname: Lu, Dayun
  organization: Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China
– sequence: 3
  givenname: Ran
  surname: Chen
  fullname: Chen, Ran
  organization: University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China; State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China
– sequence: 4
  givenname: Youpei
  surname: Lin
  fullname: Lin, Youpei
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 5
  givenname: Hongwen
  surname: Zhu
  fullname: Zhu, Hongwen
  organization: Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
– sequence: 6
  givenname: Zhou
  surname: Zhang
  fullname: Zhang, Zhou
  organization: Burning Rock Biotech, Shanghai 201114, China
– sequence: 7
  givenname: Shangli
  surname: Cai
  fullname: Cai, Shangli
  organization: Burning Rock Biotech, Shanghai 201114, China
– sequence: 8
  givenname: Peng
  surname: Cui
  fullname: Cui, Peng
  organization: Burning Rock Biotech, Shanghai 201114, China
– sequence: 9
  givenname: Guohe
  surname: Song
  fullname: Song, Guohe
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 10
  givenname: Dongning
  surname: Rao
  fullname: Rao, Dongning
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 11
  givenname: Xinpei
  surname: Yi
  fullname: Yi, Xinpei
  organization: Lester and Sue Smith Breast Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
– sequence: 12
  givenname: Yingcheng
  surname: Wu
  fullname: Wu, Yingcheng
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 13
  givenname: Nixue
  surname: Song
  fullname: Song, Nixue
  organization: Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China
– sequence: 14
  givenname: Fen
  surname: Liu
  fullname: Liu, Fen
  organization: University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China; State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China
– sequence: 15
  givenname: Yunhao
  surname: Zou
  fullname: Zou, Yunhao
  organization: University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China; State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China
– sequence: 16
  givenname: Shu
  surname: Zhang
  fullname: Zhang, Shu
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 17
  givenname: Xiaoming
  surname: Zhang
  fullname: Zhang, Xiaoming
  organization: Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
– sequence: 18
  givenname: Xiaoying
  surname: Wang
  fullname: Wang, Xiaoying
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 19
  givenname: Shuangjian
  surname: Qiu
  fullname: Qiu, Shuangjian
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China
– sequence: 20
  givenname: Jian
  surname: Zhou
  fullname: Zhou, Jian
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China; Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
– sequence: 21
  givenname: Shisheng
  surname: Wang
  fullname: Wang, Shisheng
  organization: Frontiers Science Center for Disease-related Molecular Network, Institutes for Systems Genetics, Key Lab of Transplant Engineering and Immunology, MOH, West China Hospital, Sichuan University, Chengdu 610041, China
– sequence: 22
  givenname: Xu
  surname: Zhang
  fullname: Zhang, Xu
  organization: Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; Shanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, 555 Zuchongzhi Road, Shanghai 201203, China
– sequence: 23
  givenname: Yongyong
  surname: Shi
  fullname: Shi, Yongyong
  organization: Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), The Collaborative Innovation Center for Brain Science, Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, China
– sequence: 24
  givenname: Daniel
  surname: Figeys
  fullname: Figeys, Daniel
  organization: Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; Shanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, 555 Zuchongzhi Road, Shanghai 201203, China
– sequence: 25
  givenname: Li
  surname: Ding
  fullname: Ding, Li
  organization: Department of Medicine, McDonnell Genome Institute, Siteman Cancer Center, Washington University, St. Louis, MI 63108, USA
– sequence: 26
  givenname: Pei
  surname: Wang
  fullname: Wang, Pei
  organization: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NewYork, NY 10029, USA
– sequence: 27
  givenname: Bing
  surname: Zhang
  fullname: Zhang, Bing
  organization: Lester and Sue Smith Breast Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
– sequence: 28
  givenname: Henry
  surname: Rodriguez
  fullname: Rodriguez, Henry
  organization: Office of Cancer Clinical Proteomics Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
– sequence: 29
  givenname: Qiang
  surname: Gao
  fullname: Gao, Qiang
  email: gaoqiang@fudan.edu.cn
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China; Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200433, China. Electronic address: gaoqiang@fudan.edu.cn
– sequence: 30
  givenname: Daming
  surname: Gao
  fullname: Gao, Daming
  email: dgao@sibcb.ac.cn
  organization: University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China; State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China. Electronic address: dgao@sibcb.ac.cn
– sequence: 31
  givenname: Hu
  surname: Zhou
  fullname: Zhou, Hu
  email: zhouhu@simm.ac.cn
  organization: Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, Number 19A Yuquan Road, Beijing 100049, China; Shanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, 555 Zuchongzhi Road, Shanghai 201203, China. Electronic address: zhouhu@simm.ac.cn
– sequence: 32
  givenname: Jia
  surname: Fan
  fullname: Fan, Jia
  email: fan.jia@zs-hospital.sh.cn
  organization: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai 200032, China; Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. Electronic address: fan.jia@zs-hospital.sh.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34971568$$D View this record in MEDLINE/PubMed
BookMark eNpNkEtLxDAYRYOMOA_9BYJ06aY1SdOkWcrgCwZ0oeuSpl9nMrRJTVJh_PV2cARX9y7uOYu7RDPrLCB0TXBGMOF3-0xr6LqMYkoyQjOM-RlakFKUac5LPvvX52gZwh5PFBHyAs1zJgUpeLlA-zfvIrgtWNcbneid8kpH8OZbReNsYhqw0bQGQqI7Y41WXXdIPHTwpWxMwlhvvRuHkLg2MTZ6tYNhIo8m1ym7NU4rr81kV5fovFVdgKtTrtDH48P7-jndvD69rO83qWa0iGmOFcMC50TKnGsompwIUdeCMy6LVrSU1YSVApgoJa1L3ogiB66o5iUIRhldodtf7-Dd5wghVr0Jx6eUBTeGinJSSEolkdP05jQd6x6aavCmV_5Q_f1DfwAKbmy9
CitedBy_id crossref_primary_10_1007_s10719_022_10085_5
crossref_primary_10_1186_s13046_023_02813_y
crossref_primary_10_1007_s13402_022_00736_y
crossref_primary_10_1007_s12072_023_10552_7
crossref_primary_10_1158_0008_5472_CAN_23_3298
crossref_primary_10_1038_s41420_025_02349_4
crossref_primary_10_3389_fimmu_2022_1051273
crossref_primary_10_3389_fphar_2023_1234342
crossref_primary_10_1038_s41467_024_54352_5
crossref_primary_10_1038_s41467_023_36462_8
crossref_primary_10_1097_HC9_0000000000000597
crossref_primary_10_3390_cancers16162889
crossref_primary_10_1051_vcm_2025012
crossref_primary_10_1016_j_cell_2024_05_039
crossref_primary_10_1002_mco2_70341
crossref_primary_10_1093_oncolo_oyae132
crossref_primary_10_1038_s41587_025_02659_z
crossref_primary_10_1093_bib_bbac450
crossref_primary_10_1186_s13148_022_01393_6
crossref_primary_10_3390_ijms25031782
crossref_primary_10_1111_jgh_16915
crossref_primary_10_1007_s00535_024_02090_2
crossref_primary_10_1136_gutjnl_2022_327209
crossref_primary_10_1186_s13046_024_03036_5
crossref_primary_10_1158_2326_6066_CIR_21_1101
crossref_primary_10_3390_immuno5030040
crossref_primary_10_1159_000546574
crossref_primary_10_1136_jcp_2024_209914
crossref_primary_10_1016_j_lfs_2025_123713
crossref_primary_10_1002_mas_21827
crossref_primary_10_3390_ijms241914609
crossref_primary_10_1186_s12964_025_02207_x
crossref_primary_10_1146_annurev_pharmtox_022723_113921
crossref_primary_10_1093_bib_bbad331
crossref_primary_10_1016_j_canlet_2023_216305
crossref_primary_10_1158_2159_8290_CD_24_1383
crossref_primary_10_1016_j_canlet_2022_215853
crossref_primary_10_1016_j_critrevonc_2025_104784
crossref_primary_10_1007_s00204_023_03583_4
crossref_primary_10_1186_s12935_024_03251_2
crossref_primary_10_1038_s43018_022_00479_7
crossref_primary_10_1097_CM9_0000000000002459
crossref_primary_10_1038_s41467_024_44795_1
crossref_primary_10_1097_JS9_0000000000000636
crossref_primary_10_3389_fimmu_2024_1477267
crossref_primary_10_1136_gutjnl_2021_326514
crossref_primary_10_3389_fimmu_2024_1482291
crossref_primary_10_3390_cancers16142596
crossref_primary_10_1038_s41421_024_00688_7
crossref_primary_10_3390_biomedicines13061369
crossref_primary_10_3389_fphar_2024_1440985
crossref_primary_10_1097_HEP_0000000000001423
crossref_primary_10_1182_blood_2022016033
crossref_primary_10_1002_mog2_70012
crossref_primary_10_1016_j_canlet_2025_217540
crossref_primary_10_3389_fonc_2023_1169537
crossref_primary_10_1007_s00432_024_05869_1
crossref_primary_10_3390_cancers16040801
crossref_primary_10_1016_j_ccell_2024_03_004
crossref_primary_10_1016_j_neo_2023_100882
crossref_primary_10_1016_j_ajpath_2024_10_021
crossref_primary_10_1002_hep_32558
crossref_primary_10_1186_s12916_025_04263_z
crossref_primary_10_1016_j_jhep_2025_07_008
crossref_primary_10_1038_s41467_024_44748_8
crossref_primary_10_3390_toxins16060236
crossref_primary_10_1016_j_clinre_2022_101991
crossref_primary_10_1186_s12916_024_03482_0
crossref_primary_10_1186_s13046_022_02386_2
crossref_primary_10_1186_s13045_024_01527_8
crossref_primary_10_1111_liv_16015
crossref_primary_10_1158_0008_5472_CAN_24_0147
crossref_primary_10_1038_s41420_024_02079_z
crossref_primary_10_1080_14737140_2023_2170878
crossref_primary_10_1016_j_ijbiomac_2025_147668
crossref_primary_10_1016_j_isci_2024_111657
crossref_primary_10_1016_j_intimp_2023_110948
crossref_primary_10_1016_j_tranon_2025_102446
crossref_primary_10_1186_s12967_024_05854_9
crossref_primary_10_3390_cancers15225309
crossref_primary_10_3389_fonc_2022_924696
crossref_primary_10_3390_biomedicines10051022
crossref_primary_10_1007_s00432_023_04858_0
crossref_primary_10_1016_j_phymed_2024_155790
crossref_primary_10_1097_HEP_0000000000001085
crossref_primary_10_1038_s41388_023_02760_0
crossref_primary_10_1038_s41698_025_00816_w
crossref_primary_10_1016_j_heliyon_2024_e30781
crossref_primary_10_25259_Cytojournal_232_2024
crossref_primary_10_1186_s12885_025_13888_5
crossref_primary_10_1093_bib_bbaf143
crossref_primary_10_1126_science_adl6173
crossref_primary_10_1038_s44319_024_00075_z
crossref_primary_10_1097_HEP_0000000000000688
crossref_primary_10_1172_JCI187024
crossref_primary_10_3390_biology13020083
crossref_primary_10_1007_s00432_024_05723_4
crossref_primary_10_1136_jitc_2022_004892
crossref_primary_10_1097_HEP_0000000000001096
crossref_primary_10_1038_s41417_023_00673_4
crossref_primary_10_1016_j_ccell_2023_06_009
crossref_primary_10_1093_carcin_bgad009
crossref_primary_10_1186_s13046_024_03174_w
crossref_primary_10_1016_j_jhep_2022_05_043
crossref_primary_10_1097_HEP_0000000000000534
crossref_primary_10_1126_scitranslmed_adg3358
crossref_primary_10_1002_advs_202309010
crossref_primary_10_1158_0008_5472_CAN_24_2097
crossref_primary_10_1007_s12072_023_10556_3
crossref_primary_10_1016_j_canlet_2023_216123
crossref_primary_10_3389_fimmu_2022_871769
crossref_primary_10_3390_cancers16203542
crossref_primary_10_1038_s41419_023_06309_7
crossref_primary_10_1159_000530273
crossref_primary_10_1186_s12935_024_03370_w
crossref_primary_10_1016_j_jhep_2025_03_028
crossref_primary_10_1097_HC9_0000000000000074
crossref_primary_10_1111_jcmm_70363
crossref_primary_10_1038_s41575_022_00741_4
crossref_primary_10_1186_s12957_023_02970_6
crossref_primary_10_1002_EXP_20220170
crossref_primary_10_1016_j_cell_2023_12_004
crossref_primary_10_1186_s12885_024_13081_0
crossref_primary_10_1093_carcin_bgad023
crossref_primary_10_1177_15330338221128689
crossref_primary_10_3390_cancers16091761
crossref_primary_10_1136_gutjnl_2023_330748
crossref_primary_10_3390_biom13040685
crossref_primary_10_1016_j_compbiomed_2023_107572
crossref_primary_10_1096_fj_202402088R
crossref_primary_10_1038_s41467_024_55665_1
crossref_primary_10_1186_s12967_024_05750_2
crossref_primary_10_1016_j_bbadis_2024_167276
crossref_primary_10_1038_s41598_025_90997_y
crossref_primary_10_1111_jcmm_70272
crossref_primary_10_3390_biom15081177
crossref_primary_10_1097_HEP_0000000000001283
crossref_primary_10_1007_s12072_022_10445_1
crossref_primary_10_3390_cells12121663
crossref_primary_10_3390_cells12091216
crossref_primary_10_1038_s41551_025_01448_y
crossref_primary_10_1186_s13148_022_01413_5
crossref_primary_10_1038_s41698_024_00783_8
crossref_primary_10_1371_journal_pone_0300441
crossref_primary_10_1038_s41422_022_00650_w
crossref_primary_10_1097_CM9_0000000000003705
crossref_primary_10_1007_s12672_025_03314_4
crossref_primary_10_1111_liv_15984
crossref_primary_10_1186_s13046_025_03444_1
crossref_primary_10_1002_inmd_70048
crossref_primary_10_1093_nsr_nwad167
crossref_primary_10_7717_peerj_19083
crossref_primary_10_1016_j_cej_2024_152574
crossref_primary_10_1097_MOT_0000000000001209
crossref_primary_10_3389_fimmu_2023_1165510
crossref_primary_10_1016_j_jhep_2024_04_010
crossref_primary_10_1016_j_omtn_2023_102047
crossref_primary_10_3350_cmh_2024_0998
crossref_primary_10_3389_fcimb_2023_1240743
crossref_primary_10_1016_j_canlet_2025_217937
crossref_primary_10_1038_s41597_023_02257_1
crossref_primary_10_1038_s41467_022_34249_x
crossref_primary_10_1007_s44272_025_00036_0
crossref_primary_10_3390_cells11193088
crossref_primary_10_1186_s12967_024_05529_5
crossref_primary_10_1016_j_intonc_2024_10_003
crossref_primary_10_3389_fmed_2024_1435620
crossref_primary_10_1097_HC9_0000000000000204
crossref_primary_10_1007_s44272_024_00016_w
crossref_primary_10_4251_wjgo_v16_i4_1344
crossref_primary_10_1016_j_jare_2025_08_038
crossref_primary_10_1002_advs_202503499
crossref_primary_10_1186_s12935_022_02550_w
crossref_primary_10_1002_cac2_12513
crossref_primary_10_1016_j_ygeno_2024_110889
crossref_primary_10_3350_cmh_2024_0895
crossref_primary_10_1002_advs_202412740
crossref_primary_10_1007_s10238_024_01350_y
crossref_primary_10_1007_s00428_025_04067_9
crossref_primary_10_1016_j_dld_2023_08_052
crossref_primary_10_15252_embr_202255762
crossref_primary_10_1016_j_heliyon_2024_e32352
crossref_primary_10_1158_2159_8290_CD_21_1640
crossref_primary_10_12998_wjcc_v10_i32_11889
crossref_primary_10_1007_s11547_023_01597_7
crossref_primary_10_1016_j_ejps_2025_107274
crossref_primary_10_1245_s10434_024_16799_0
crossref_primary_10_52601_bpr_2024_240053
crossref_primary_10_1038_s41418_025_01460_4
crossref_primary_10_1016_j_tranon_2025_102290
crossref_primary_10_1097_HEP_0000000000001138
crossref_primary_10_1186_s12935_025_03791_1
crossref_primary_10_1371_journal_pone_0315324
crossref_primary_10_3389_fcimb_2025_1596688
crossref_primary_10_3389_fonc_2022_1090634
crossref_primary_10_3390_cancers16101886
crossref_primary_10_1002_hep_32624
crossref_primary_10_1002_pmic_202100407
crossref_primary_10_3389_fmicb_2022_1015140
crossref_primary_10_1158_2159_8290_CD_23_0282
crossref_primary_10_3389_fphar_2025_1495280
ContentType Journal Article
Copyright Copyright © 2021 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2021 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ccell.2021.12.006
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1878-3686
ExternalDocumentID 34971568
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
0R~
0SF
1~5
29B
2WC
4.4
457
4G.
53G
5GY
62-
6J9
7-5
AACTN
AAEDT
AAEDW
AAFTH
AAKRW
AAKUH
AALRI
AAMRU
AAVLU
AAXUO
ABJNI
ABMAC
ABVKL
ACGFO
ACGFS
ADBBV
ADEZE
ADVLN
AEFWE
AENEX
AEXQZ
AFTJW
AGKMS
AITUG
AKAPO
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
F5P
FCP
FDB
FEDTE
FIRID
HVGLF
IH2
IHE
IXB
J1W
JIG
M3Z
M41
NPM
O-L
O9-
OK1
P2P
RCE
ROL
RPZ
SES
SSZ
TR2
UDS
7X8
AAFWJ
AAYWO
ABDGV
ACVFH
ADCNI
AEUPX
AFPUW
AIGII
AKBMS
AKYEP
APXCP
EFKBS
ID FETCH-LOGICAL-c425t-30a4070319936ce5d3177bb764695f7f24b1487e47892b86d753e6a2c68e74242
IEDL.DBID 7X8
ISICitedReferencesCount 235
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000744691500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1878-3686
IngestDate Sun Sep 28 08:28:59 EDT 2025
Wed Feb 19 02:26:50 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords prognostic biomarkers
molecular subgroups
oncogenic drivers
proteogenomics
intrahepatic cholangiocarcinoma
FGFR2 fusion
Language English
License Copyright © 2021 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c425t-30a4070319936ce5d3177bb764695f7f24b1487e47892b86d753e6a2c68e74242
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 34971568
PQID 2615922919
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2615922919
pubmed_primary_34971568
PublicationCentury 2000
PublicationDate 2022-01-10
PublicationDateYYYYMMDD 2022-01-10
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-10
  day: 10
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer cell
PublicationTitleAlternate Cancer Cell
PublicationYear 2022
SSID ssj0016179
Score 2.7076976
Snippet We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) using paired tumor and adjacent liver tissues from 262 patients....
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 70
SubjectTerms Bile Duct Neoplasms - genetics
Bile Duct Neoplasms - pathology
Bile Ducts, Intrahepatic - pathology
Cholangiocarcinoma - genetics
Cholangiocarcinoma - pathology
Humans
Liver - pathology
Mutation - genetics
Prognosis
Proteogenomics - methods
Proteomics
Tumor Microenvironment - immunology
Title Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/34971568
https://www.proquest.com/docview/2615922919
Volume 40
WOSCitedRecordID wos000744691500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAIsSFfSmbjMQ1orET2zkhhKg40KoHQL1FtuOIIJqUpkXi75nJQk9ISFx8yyJ77Hlv_GaGkCsjI2NSyz3LfOEFWvc8zbX0hLDYCZ6LtEqkfXmUw6Eaj6NRE3ArG1lleyZWB3VSWIyRXwPSDyPGIj-6mX542DUKb1ebFhqrpMMByqBVy_HyFgG8M8JfX6EEQCjRVh2q9F0WI-NAEJlfxQN74neMWfma_vZ__3KHbDUok97WZrFLVly-RzYGzT36PnkbYXmGAgu0TjJL7U_V5jopk2ZJLSJyJW1TJ9-_KPZXAeA9p-XCVNkgJS1SmmF4-NWhMhvfVGAENAMPOYNPFRN9QJ779093D17TdcGzsH_nHu_poKpqD8hFWBcmgDCkMVIAkQ5TmbLAAIWSLpAqYkaJBAiPE5pZoRzw7IAdkrW8yN0xoaHWOjHG97nUgARgUOAxNaBKF3Cg3l1y2c5iDFaNC6JzVyzKeDmPXXJUL0U8rctvxDyIJLBOdfKHp0_JJsN8hR7q9s5IJ4U97c7Juv2cZ-XsojIXGIejwTc3-ctM
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proteogenomic+characterization+identifies+clinically+relevant+subgroups+of+intrahepatic+cholangiocarcinoma&rft.jtitle=Cancer+cell&rft.au=Dong%2C+Liangqing&rft.au=Lu%2C+Dayun&rft.au=Chen%2C+Ran&rft.au=Lin%2C+Youpei&rft.date=2022-01-10&rft.eissn=1878-3686&rft.volume=40&rft.issue=1&rft.spage=70&rft_id=info:doi/10.1016%2Fj.ccell.2021.12.006&rft_id=info%3Apmid%2F34971568&rft_id=info%3Apmid%2F34971568&rft.externalDocID=34971568
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1878-3686&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1878-3686&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1878-3686&client=summon